You just read:

BioSight Completed Patient Enrollment and Treatment in its Extended Acute Leukemia Phase I/II Clinical Trial with BST-236, a Novel Cytarabine Pro-Drug

News provided by

BioSight, Ltd

Aug 09, 2017, 08:00 ET